Vidarabine (Synonyms: Ara-A; Adenine Arabinoside; 9-β-D-Arabinofuranosyladenine)

Name: Vidarabine
Brand: MedChemExpress
SKU: HY-B0277
Rating: 5.0 (7 reviews)

Cat. No.: HY-B0277 Purity: 98.85%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Vidarabine (Ara-A) is a nucleoside antibiotic isolated from Streptomyces, and a metabolite of Vidarabine phosphate (HY-B0277A). Vidarabine selectively inhibits viral DNA polymerase and cellular ribonucleotide reductase, thereby blocking viral replication. Vidarabine phosphate also exhibits antifungal activity, induces late-stage cellular apoptosis, and causes cell cycle arrest. Vidarabine phosphate can be used in research related to severe chronic active Epstein-Barr virus (EBV) infection, herpes infection, and candidiasis.

For research use only. We do not sell to patients.

Vidarabine Chemical Structure

CAS No. : 5536-17-4

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	Get quote
10 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

Other Forms of Vidarabine:

7 Publications Citing Use of MCE Vidarabine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HSV Isoform Specific Products:

View All Isoforms

HSV-1 HSV-2 HSV

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

View All DNA/RNA Synthesis Isoform Specific Products:

View All Isoforms

RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

HSV-2

11.3 μg/mL (IC₅₀)

HSV-1

9.3 μg/mL (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	IC₅₀	24.8 μM Compound: ara A	Antitumor activity was evaluated against CEM cell line Antitumor activity was evaluated against CEM cell line	[PMID: 9871764]
CCRF-CEM	IC₅₀	24.8 μM Compound: araA	Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells	10.1016/S0960-894X(97)00044-9
CCRF-HSB-2	IC₅₀	12.9 μg/mL Compound: araA	Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells. Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.	[PMID: 9216836]
Caco-2	IC₅₀	62 nM Compound: ara-A, vidarabine	Inhibition of human DPP4 from human Caco-2 cells Inhibition of human DPP4 from human Caco-2 cells	[PMID: 20000418]
HEL	EC₅₀	10 μM Compound: ara-A, vidarabine	Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of virus-induced cytopathicity in presence of vildagliptin Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of virus-induced cytopathicity in presence of vildagliptin	[PMID: 20000418]
HEL	EC₅₀	35 μM Compound: ara-A, vidarabine	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20000418]
HEL	EC₅₀	42 μM Compound: ara-A, vidarabine	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity in presence of vildagliptin Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity in presence of vildagliptin	[PMID: 20000418]
HEL	EC₅₀	8.3 μM Compound: ara-A, vidarabine	Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Vaccinia virus Lederle infected in HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20000418]
HEL	ED₅₀	1.17 μg/mL Compound: araA	Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells. Antiviral activity against varicella zoster virus (VZV) Oka strain in HEL (human erythroleukemia) cells.	[PMID: 9216836]
HEL	ED₅₀	17.1 μg/mL Compound: araA	Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells. Antiviral activity against herpes simplex virus-1 VR-3 strain in HEL (human erythroleukemia) cells.	[PMID: 9216836]
HEL	ED₅₀	6.45 μg/mL Compound: araA	Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells. Antiviral activity against human cytomegalovirus (HCMV) AD 169 strain HEL (human erythroleukemia) cells.	[PMID: 9216836]
HEL	ED₅₀	6.6 μg/mL Compound: araA	Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells. Antiviral activity against herpes simplex virus-2 (HSV-2) Ms strain in HEL (human erythroleukemia) cells.	[PMID: 9216836]
HFF	CC₅₀	90 μM Compound: 1	Cytotoxicity against HFF in presence of deoxy-coformycin Cytotoxicity against HFF in presence of deoxy-coformycin	[PMID: 19097789]
HFF	CC₅₀	> 100 μM Compound: 1	Cytotoxicity against HFF Cytotoxicity against HFF	[PMID: 19097789]
HFF	IC₅₀	2 μM Compound: Ara-A	Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells assessed as reduction in plaque formation after 3 days Antiviral activity against Vaccinia virus Copenhagen infected in HFF cells assessed as reduction in plaque formation after 3 days	[PMID: 21641218]
HL-60	IC₅₀	20.9 μg/mL Compound: ara-A	The cytotoxic activity in HL-60 cells The cytotoxic activity in HL-60 cells	[PMID: 9371251]
KB	IC₅₀	39 μg/mL Compound: ara-A	In vitro cytotoxicity against herpes simplex virus type-1 (HSV-1) HF strain in infected KB cells In vitro cytotoxicity against herpes simplex virus type-1 (HSV-1) HF strain in infected KB cells	[PMID: 2838633]
KB	IC₅₀	5.6 μg/mL Compound: ara-A	Inhibitory activity against herpes simplex virus type-1 (HSV-1) replication in KB cells Inhibitory activity against herpes simplex virus type-1 (HSV-1) replication in KB cells	[PMID: 2838633]
L1210	IC₅₀	14.2 μM Compound: ara A	Antitumor activity was evaluated against L1210 cell line Antitumor activity was evaluated against L1210 cell line	[PMID: 9871764]
L1210	IC₅₀	14.2 μM Compound: araA	Tested for its antiproliferative activity on murine leukemia L1210 cells Tested for its antiproliferative activity on murine leukemia L1210 cells	10.1016/S0960-894X(97)00044-9
MOLT-4	IC₅₀	11.9 μM Compound: ara A	Antitumor activity was evaluated against Molt4/C8 cell line Antitumor activity was evaluated against Molt4/C8 cell line	[PMID: 9871764]
MOLT-4	IC₅₀	11.9 μM Compound: araA	Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells	10.1016/S0960-894X(97)00044-9
PRK	IC₅₀	0.4 μg/mL Compound: ara-A	Compound was evaluated for antiviral activity in rabbit kidney cells infected with vaccinia virus Compound was evaluated for antiviral activity in rabbit kidney cells infected with vaccinia virus	[PMID: 6267280]
PRK	IC₅₀	10 μg/mL Compound: ara-A	Concentration required to inhibit incorporation of [1,'2'-3H]dUrd into DNA of primary rabbit kidney (PRK) cells by 50% Concentration required to inhibit incorporation of [1,'2'-3H]dUrd into DNA of primary rabbit kidney (PRK) cells by 50%	[PMID: 6267280]
PRK	IC₅₀	10 μg/mL Compound: ara-A	Concentration required to reduce TK-HSV-1 (B2006) induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells Concentration required to reduce TK-HSV-1 (B2006) induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells	[PMID: 6267280]
PRK	IC₅₀	1 μg/mL Compound: ara-A	Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% was measured by the addition of [1,'2'-3H]dUrd Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% was measured by the addition of [1,'2'-3H]dUrd	[PMID: 6267280]
PRK	IC₅₀	1 μg/mL Compound: ara-A	Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% was measured by the addition of [Me-3H]-dThd Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% was measured by the addition of [Me-3H]-dThd	[PMID: 6267280]
PRK	IC₅₀	20 μg/mL Compound: ara-A	Concentration required to inhibit incorporation of [Me-3H]-dThd into DNA of primary rabbit kidney (PRK) cells by 50% Concentration required to inhibit incorporation of [Me-3H]-dThd into DNA of primary rabbit kidney (PRK) cells by 50%	[PMID: 6267280]
PRK	IC₅₀	3 μg/mL Compound: ara-A	Concentration required to reduce HSV-2 induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells; 2-4 Concentration required to reduce HSV-2 induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells; 2-4	[PMID: 6267280]
PRK	IC₅₀	4 μg/mL Compound: ara-A	Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% was measured Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% was measured	[PMID: 6267280]
PRK	IC₅₀	7 μg/mL Compound: ara-A	Concentration required to reduce HSV-1 induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells; 4-10 Concentration required to reduce HSV-1 induced cytopathogenicity by 50% in primary rabbit kidney (PRK) cells; 4-10	[PMID: 6267280]
Vero	CC₅₀	38 μM Compound: araA	Cytotoxicity against african green monkey Vero cells after 2 days Cytotoxicity against african green monkey Vero cells after 2 days	[PMID: 17438061]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	26.5 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	28 μM Compound: araA	Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	35 μM Compound: araA	Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	37.8 μM Compound: VDB	Antiviral activity against thymidine kinase deficient Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against thymidine kinase deficient Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	46.1 μM Compound: VDB	Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells harboring stop mutation thymidine kinase by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells harboring stop mutation thymidine kinase by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	7 μM Compound: araA	Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]

In Vitro

Vidarabine (18-1200 μg/mL; 48 h) exhibits bactericidal activity against Candida albicans, with an MIC₅₀ and MFC of 150 μg/mL and 300 μg/mL, respectively^[3].
Vidarabine (150-300 μg/mL; 4-24 h) induces intracellular ROS accumulation, nuclear pyknosis, late-stage apoptosis and cell cycle arrest in Candida albicans cells, and reduces their ergosterol content^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

267.25

Formula

C₁₀H₁₃N₅O₄

CAS No.

5536-17-4

Appearance

Solid

Color

White to off-white

SMILES

OC[C@@H]1[C@@H](O)[C@H](O)[C@H](N2C3=NC=NC(N)=C3N=C2)O1

Structure Classification

Initial Source

Microorganisms

Streptomyces

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (187.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.7418 mL	18.7091 mL	37.4181 mL
5 mM	0.7484 mL	3.7418 mL	7.4836 mL
10 mM	0.3742 mL	1.8709 mL	3.7418 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.35%

Select Batch:

Data Sheet (279 KB) SDS (419 KB)

COA (255 KB) HNMR (114 KB) RP-HPLC (260 KB) MS (155 KB)

Handling Instructions (2659 KB)

References

[1]. Kimura H, et al. Vidarabine therapy for severe chronic active Epstein-Barr virus infection. J Pediatr Hematol Oncol. 2001;23(5):294-299.

[2]. Gough AW, et al. Comparison of the neonatal toxicity of two antiviral agents: Vidarabine phosphate and cytarabine. Toxicology and applied pharmacology. 1982 Oct 1;66(1):143-52.

[3]. Gavandi TC, et al. Vidarabine as a novel antifungal agent against Candida albicans: insights on mechanism of action. Int Microbiol. 2025;28(3):589-602.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.7418 mL	18.7091 mL	37.4181 mL	93.5454 mL
	5 mM	0.7484 mL	3.7418 mL	7.4836 mL	18.7091 mL
	10 mM	0.3742 mL	1.8709 mL	3.7418 mL	9.3545 mL
	15 mM	0.2495 mL	1.2473 mL	2.4945 mL	6.2364 mL
	20 mM	0.1871 mL	0.9355 mL	1.8709 mL	4.6773 mL
	25 mM	0.1497 mL	0.7484 mL	1.4967 mL	3.7418 mL
	30 mM	0.1247 mL	0.6236 mL	1.2473 mL	3.1182 mL
	40 mM	0.0935 mL	0.4677 mL	0.9355 mL	2.3386 mL
	50 mM	0.0748 mL	0.3742 mL	0.7484 mL	1.8709 mL
	60 mM	0.0624 mL	0.3118 mL	0.6236 mL	1.5591 mL
	80 mM	0.0468 mL	0.2339 mL	0.4677 mL	1.1693 mL
	100 mM	0.0374 mL	0.1871 mL	0.3742 mL	0.9355 mL

Vidarabine Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Vidarabine5536-17-4Ara-A Adenine Arabinoside 9-β-D-ArabinofuranosyladenineHSVFungalReactive Oxygen Species (ROS)EBVAntibioticApoptosisDNA/RNA SynthesisDrug MetaboliteHerpes simplex virusEpstein-Barr VirusInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Vidarabine (Synonyms: Ara-A; Adenine Arabinoside; 9-β-D-Arabinofuranosyladenine)

Customer Review

Other Forms of Vidarabine:

Vidarabine Related Antibodies

7 Publications Citing Use of MCE Vidarabine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HSV Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

View All DNA/RNA Synthesis Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Vidarabine Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Vidarabine Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report